BIOCRYST PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $4.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $4.20M, a 3550.43% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $86.00K, a 18.10% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $366.00K, a 16.44% decline from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $438.00K, a 90.67% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $4.70M, a 521.85% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $755.00K, a 50.85% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.20M 10-Q · filed 2026-08-05 | $4.20M derived: sum of 3 quarters · filed 2026-08-05 | $4.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $4.20M 10-Q · filed 2026-05-06 | $4.20M derived: sum of 2 quarters · filed 2026-05-06 | $4.28M derived: sum of 3 quarters · filed 2026-05-06 | $4.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $86.00K derived: sum of 2 quarters · filed 2026-02-26 | $251.00K derived: sum of 3 quarters · filed 2026-08-05 | $366.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $251.00K derived: sum of 2 quarters · filed 2026-08-05 | $366.00K 10-Q · filed 2025-11-04 | $543.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $280.00K 10-Q · filed 2026-08-05 | $457.00K derived: sum of 3 quarters · filed 2026-08-05 | $562.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $115.00K 10-Q · filed 2026-05-06 | $292.00K derived: sum of 2 quarters · filed 2026-05-06 | $397.00K derived: sum of 3 quarters · filed 2026-05-06 | $397.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $282.00K derived: sum of 2 quarters · filed 2026-02-26 | $282.00K derived: sum of 3 quarters · filed 2026-02-26 | $438.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $105.00K derived: sum of 2 quarters · filed 2025-11-04 | $261.00K 10-Q · filed 2025-11-04 | $494.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $156.00K 10-Q · filed 2025-08-05 | $389.00K derived: sum of 3 quarters · filed 2026-02-26 | $4.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $156.00K 10-Q · filed 2025-05-06 | $389.00K derived: sum of 2 quarters · filed 2026-02-26 | $4.50M derived: sum of 3 quarters · filed 2026-02-26 | $4.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.34M derived: sum of 2 quarters · filed 2026-02-26 | $4.60M derived: sum of 3 quarters · filed 2026-02-26 | $4.70M 10-K · filed 2026-02-26 |
| 2023-09-30 | $4.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $4.37M derived: sum of 2 quarters · filed 2024-11-05 | $4.46M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $255.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $350.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $95.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $755.00K 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $1.54M 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |